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The Ron tyrosine kinase receptor shares with the members of its subfamily (Met and Sea) a unique func-
tional feature: the control of cell dissociation, motility, and invasion of extracellular matrices (scattering). The
mature Ron protein is a heterodimer of disulfide-linked a and b chains, originated by proteolytic cleavage of
a single-chain precursor of 185 kDa. In a human gastric cancer cell line (KATO-III), we found abnormal ac-
cumulation of an uncleaved single-chain protein (D-Ron) of 165 kDa; this molecule is encoded by a transcript
differing from the full-length RONmRNA by an in-frame deletion of 49 amino acids in the b-chain extracellular
domain. The deleted transcript originates by an alternatively spliced cassette exon of 147 bp, flanked by two
short introns. The D-Ron tyrosine kinase is constitutively activated by disulfide-linked intracellular oligomer-
ization because it contains an uneven number of cysteine residues. Oligomerization and constitutive tyrosine
phosphorylation of the full-size Ron was obtained by site-directed mutagenesis of a single cysteine residue in
the region encoded by the cassette exon, mimicking that occurring in the D-Ron isoform. Inhibition of
thiol-mediated intermolecular disulfide bonding prevented D-Ron oligomerization. The intracellular activation
of Ron is followed by acquisition of invasive properties in vitro. These data (i) provide a novel molecular
mechanism for posttranscriptional activation of a tyrosine kinase receptor protein and (ii) suggest a role for
the Ron receptor in progression toward malignancy.
One of the cellular mechanisms responsible for generating
protein diversity is alternative RNA splicing, producing multi-
ple isoforms from a single gene. Several examples have been
described for transcripts encoding proteins involved in cellular
signal transduction, including fibroblast growth factor, platelet-
derived growth factor, epidermal growth factor, nerve growth
factor, and insulin receptors and the cytoplasmic kinases Src
and Lyn (for a review, see references 3 and 6). Different iso-
forms generated by alternative splicing have also been de-
scribed for Met, the hepatocyte growth factor receptor (HGF)
(22, 35). Met is the prototype of a tyrosine kinase receptor
family, including the product of avian sea (16) and Ron, the hu-
man receptor for the macrophage-stimulating protein (MSP)
(13, 36).
Ron is a heterodimeric protein (p185RON) composed of a
and b subunits derived from proteolytic cleavage of a common
precursor of 170 kDa (13), as previously described for the
HGF receptor (14). p185RON is expressed in several epithelial
tissues, in granulocytes, and in monocytes as the translation
product of a 5.0-kb transcript. The extracellular domain of Ron
binds the ligand; the membrane-spanning b subunit contains
an active tyrosine kinase domain (13). Other important fea-
tures common to the products of RON andMET are the major
autophosphorylation sites, made of two neighboring tyrosine
residues (23), and a multifunctional docking site located in the
receptor tail that mediates signal transduction (32). Binding of
MSP to p185RON stimulates the intrinsic tyrosine kinase activ-
ity and phosphorylation of the docking site recognized by mul-
tiple SH2 domain-containing transducer and adapter proteins.
This activates the intracellular signaling cascade eliciting a
distinctive biological response, shared by Ron and the other
members of the MET gene family: cell dissociation, motility,
and polarized growth (for a review, see reference 8).
In this paper, we report constitutive activation of the Ron
receptor by intracellular oligomerization of an uncleaved pro-
tein isoform lacking 49 amino acids in the extracellular domain
(D-Ron). This molecule originates from alternative splicing of
one cassette exon of 147 bp, because of the presence of a
noncanonical splice site consensus sequence. In a gastric car-
cinoma cell line (KATO-III), the D-RON mRNA is translated
into an uncleaved precursor protein (p165D-RON) containing an
uneven number of cysteine residues. Because of aberrant in-
termolecular disulfide bridge formation, the D-Ron tyrosine
kinase oligomerizes in the intracellular compartment and is
constitutively activated. This mechanism was mimicked by site-
directed mutagenesis of one cysteine in the Ron extracellular
domain. In the mirror experiment, inhibition of thiol-mediated
intracellular oligomerization by addition of the reducing agent
2-mercaptoethanol prevented constitutive activation. Interest-
ingly, transfection of D-RON cDNA was followed by the ac-
quisition of an invasive phenotype by recipient cells.
MATERIALS AND METHODS
Cells lines and antibodies. GTL-16 is a clonal cell line derived from a poorly
differentiated gastric carcinoma (15). The other cell lines used, KATO-III (stom-
ach carcinoma), T47D (mammary carcinoma), PT45 (pancreatic carcinoma),
MKN-1 (gastric carcinoma), SKOV3 (ovary adenocarcinoma), NIH:OVCAR3
(ovary adenocarcinoma), HOS (bone osteosarcoma), HeLa (cervix carcinoma),
COS-1 (simian kidney), and U293 (human kidney), were from the American
Type Culture Collection. Cells were grown in RPMI 1640 or in Dulbecco’s
modified Eagle medium containing 10% fetal calf serum and maintained at 378C
in a humidified atmosphere with 5% CO2. Phosphotyrosine monoclonal anti-
bodies were from Upstate Biotechnology Inc. (Lake Placid, N.Y.). Ron antibod-
ies were raised as previously described (13).
Immunoprecipitation and kinase assays. Treatment with reducing agents was
performed by growing cells for 2 h in the presence of millimolar concentrations
of 2-mercaptoethanol. Monolayers of subconfluent cell cultures were extracted
for 20 min at 48C with radioimmunoprecipitation assay (RIPA) buffer (20 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM EDTA, 0.1% sodium dodecyl sulfate
[SDS], 1% Triton X-100, 1% deoxycholate, 100 mM Na3VO4) containing pro-
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tease inhibitors. For nonreducing analysis, 50 mM iodoacetamide was included in
the lysis buffer. The cell lysates were cleared by centrifugation at 15,000 3 g for
20 min at 48C. Lysates were incubated with Ron antiserum (2.5 ml/ml of lysate)
coupled to Sepharose-protein A (20 ml of packed beads per ml of lysate) for 2 h
at 48C with agitation. Sepharose-protein A-bound proteins were washed four
times with RIPA buffer and incubated in 50 ml of kinase buffer (25 mM N-2-
hydroxyethylpiperazine-N9-2-ethanesulfonic acid [HEPES; pH 7.4], 5 mM
MnCl2, 0.05% Triton X-100, 5 mM leupeptin), supplemented with 40 mM ATP
and 10 mCi of [g-32P]ATP (specific activity, 5,000 Ci/mmol; Amersham, Little
Chalfont, United Kingdom) for 10 min at room temperature. Proteins were
separated on SDS–5 to 10% gradient polyacrylamide gels; gels were dried and
exposed for autoradiography at 2808C, using intensifying screens. In vivo ty-
rosine phosphorylation was evaluated by Western blotting (immunoblotting) of
the immunoprecipitates with phosphotyrosine antibodies. Subconfluent KATO-
III and T47D cells were treated with conditioned medium from U293 cells, either
control or MSP transfected, for 10 min at 378C. Cells were lysed in RIPA buffer
for immunoprecipitation.
Electroelution of proteins from SDS-gels. Kinase-assayed immunoprecipitates
from KATO-III cells were analyzed by SDS-polyacrylamide gel electrophoresis
(PAGE) (5 to 10% gradient gel) under nonreducing conditions. The labeled
high-molecular-weight bands of interest were located by autoradiography, ex-
cised from the dried gel, swollen in 20 ml of boiling water, mixed with an equal
volume of 13 Laemmli buffer, and analyzed by SDS-PAGE in the presence of
2-mercaptoethanol.
Cell surface biotinylation. Cell surface biotinylation was performed by using
an ECL (enhanced chemiluminescence) biotinylation kit (Amersham) as in-
structed by the supplier. After labeling, cells were extracted with ice-cold deter-
gent-insoluble matrix buffer [10 mM piperazine-N,N9-bis(2-ethanesulfonic acid)
(PIPES; pH 6.8), 100 mM NaCl, 5 mM MgCl2, 300 mM sucrose, 5 mM ethylene
glycol-bis(b-aminoethyl ether)-N,N,N9,N9-tetraacetic acid (EGTA), 1% Triton
X-100, protease inhibitors] for immunoprecipitation. Proteins were subjected to
SDS-PAGE (7% gel) and Western blotting with streptavidin-horseradish perox-
idase and an ECL kit (Amersham).
Northern (RNA) blotting. For Northern analysis, total RNA was extracted as
described by Chomczynski and Sacchi (7). Formaldehyde-agarose gel electro-
phoresis and Northern transfer were performed as described by Wahl et al. (45).
Hybridization was carried out at 658C in Rapid Hyb Buffer (Amersham) in the
presence of 106 cpm of a [a-32P]dCTP oligo-random labeled probe (specific
activity, .108 cpm/mg of DNA) per ml labeled with the Ready to Go system
(Pharmacia, Uppsala, Sweden). The specific probes used were the cDNA en-
compassing the entire coding sequence of RON and a fragment of 147 bp,
corresponding to the region of the receptor deleted in D-RON, obtained by PCR
amplification. PCR-amplified fragments shown in Fig. 3B were subjected to 1%
agarose gel electrophoresis, transferred to Hybond-N1 (Amersham) nylon
membranes, and hybridized with the full-length RON cDNA probe by using a
Direct nucleic acid labeling system kit (Amersham) as instructed by the supplier.
RT and PCR. Total RNA, extracted with guanidinium thiocyanate as de-
scribed by Chomczynski and Sacchi (7), was used for reverse transcription (RT).
The 40-ml reaction mixture contained the enzyme buffer as supplied by Bethesda
Research Laboratories, (BRL), 2 mg of RNA, 1 U of RNAsin (Promega Biotec,
Madison, Wis.) per ml, 50 pmol of the 39 PCR primer (see below), 1 mM each
deoxynucleotide triphosphate, and 10 U of Moloney murine leukemia virus
reverse transcriptase (BRL) per ml. The reaction mixture was incubated at 378C
for 1 h, the enzyme was then denatured for 3 min at 958C, and the products were
kept at 2208C. PCR was carried out on the products of the RT reactions as
follows. In a final volume of 100 ml, the reaction mixture contained 10 ml of the
products of the RT reaction as source of a template, 50 mM Tris (pH 8.4), 50
mM KCl, 25 mg of bovine serum albumin (BRL) per ml, 2 mM each deoxynucle-
otide triphosphate, 35 pmol of the 39 PCR primer, 35 pmol of the 59 PCR primer,
and a variable concentration of MgCl2. Five units of Taq polymerase (Promega
Biotec) was added, and 100 ml of mineral oil was overlaid on the reaction
mixture. Thirty cycles of denaturation, annealing, and extension were then per-
formed, using a Programmable Thermal Controller (M.J. Research, Inc.). De-
naturation was at 928C for 5 min for the first cycle and for 1 min for subsequent
cycles. Annealing temperatures varied between 45 and 638C according to the
base composition of the primers; annealing time was 1 min. The extension
temperature was 728C. The extension time was calculated by assuming a rate of
extension of 1,000 bases/min, according to the predicted length of the amplified
product. The oligomers for PCR amplifications used to clone D-RON cDNA
were designed on the basis of the RON cDNA sequence as follows: pair 1, sense
oligomer corresponding to nucleotides 2183 to 2164 (59-GAGGGCCGGGAA
GGGATTTG-39) and antisense oligomer corresponding to nucleotides 393 to
415 (59-TGCTGGTGCTGGATCCCGCGCT-39); pair 2, sense oligomer corre-
sponding to nucleotides 238 to 212 (59-CCGGTAGGGATCCTCTAGGGTC
CC-39) and antisense oligomer corresponding to nucleotides 2292 to 2315 (59-T
GCCCAGGTACCTGGTTCCTGGA-39); pair 3, sense oligomer corresponding
to nucleotides 2165 to 2184 (59-ACCAGCCGGGCTGTGCTGGT-39) and anti-
sense oligomer corresponding to nucleotides 3650 to 3672 (59-ACCTGGCTGC
GCGGAACTGCAT-39); and pair 4, sense oligomer corresponding to nucleo-
tides 3235 to 3256 (59-GTCAAGGATGTGCTGATTCCC-39) and antisense
oligomer corresponding to nucleotides 4366 to 4389 (59-TCTGTGGAGTGAG
GTACCTAATG-39).
Sequences encompassing the region of divergence between the cDNA clones
isolated from KATO-III cells were amplified on genomic DNA by using two
primers flanking this region: sense oligomer corresponding to nucleotides 2619
to 2641 (59-ATCCACCCAGTGCCAACCTAGTT-39) and antisense oligomer
corresponding to nucleotides 2873 to 2895 (59-GGCCAGATGGGGTCCCACA
GAG-39). One hundred nanograms of genomic DNA was PCR amplified by 20
touchdown cycles (11) with denaturation at 958C for 1 min, annealing tempera-
ture decreasing from 64 to 548C for 30 s, extension at 728C for 1 min, and 10
additional cycles at the lowest annealing temperature. The PCR products were
subcloned into pUC18 vector and sequenced on both strands.
DNA sequencing. Double-stranded DNA sequencing was carried out by the
dideoxynucleotide method (37), using Sequenase (U.S. Biochemicals) and the
Sequenase protocol.
Site-directed mutagenesis. The C914A-Ron mutant was created by using a
PCR cloning strategy. An antisense primer corresponding to nucleotides 2732 to
2777 (59-GGCAGACAACCATGTCCCCCCGGAACTCGTGCTGGGCGCTC
TCACC-39), including a DrdI restriction site for further cloning, was used to
mutate Cys-914 to Ala (TGC to GCC), and a sense primer, corresponding to
nucleotides 2246 to 2268 (59-CCTGGGGCCACGGTGGCCAGTGT-39), con-
taining an SfiI restriction site was used. The PCR product, double-strand se-
quenced, was inserted as an SfiI-DrdI cassette in the pMT2*RON vector. The
pMT2*C914A/RON cDNA was used for transient expression in COS-1 cells.
Transfection in COS-1 cells. The RON and D-RON cDNAs were inserted into
the pMT2* eukaryotic expression vector, which contains the major late adeno-
virus promoter and the simian virus 40 origin of replication. Subconfluent COS-1
cells were transfected with 10 mg of the expression constructs by the DNA-
calcium phosphate coprecipitation procedure (CellPhect Transfection kit; Phar-
macia) (4). Three days after transfection, expression of the D-Ron and Ron
proteins was analyzed by Western blotting.
Transwell migration and invasion assays. Transfected cells were starved for
24 h in serum-free medium before motility and invasion assays were performed,
100 h after transfection. Stimulation of cell invasiveness was determined by using
a modification of the Matrigel method (21). Polycarbonate membranes (8-mm
pore size) on the bottom of the upper compartment of the Transwells (6.5 mm;
Costar Corporation, Cambridge, Mass.) were coated with 1.2 mg of Matrigel
(Collaborative Research Incorporated, Waltham, Mass.) per ml. A total of 105
transfected cells resuspended in 200 ml of serum-free medium were placed on the
Matrigel-coated polycarbonate membrane in the upper compartment. One mil-
liliter of medium, either serum free or containing 20 ng of the stimulating factor,
was added to the lower compartment. The plates were incubated at 378C in a 5%
CO2 atmosphere saturated with H2O for 24 h. At the end of incubation, the cells
and Matrigel at the upper side of the polycarbonate filters were mechanically
removed. Cells that had invaded the Matrigel and migrated to the lower side of
the filter were fixed with 11% glutaraldehyde for 15 min at room temperature,
washed three times with distilled water, and stained with 0.1% crystal violet–20%
methanol for 20 min at room temperature. After three washes with water and
complete drying at room temperature, the crystal violet was solubilized by im-
mersing the filters in 100 ml of 10% acetic acid (5 min at room temperature). The
concentration of the solubilized crystal violet was evaluated as A595.
RESULTS
Detection of a tyrosine-phosphorylated 165-kDa Ron iso-
form (D-Ron) in a gastric carcinoma cell line. Carboxy-termi-
nus-specific antibodies against the Ron receptor (p185RON),
after immunoprecipitation and Western blotting under reduc-
ing conditions identify one single band, with an apparent mo-
lecular mass of 150 kDa, corresponding to the b chain. In cells
expressing high levels of Ron, the antibodies also identify the
pr170RON precursor as a split double band due to a different
extent of glycosylation (13). In a screening of tumor cells, the
Ron antibodies identified a protein with apparent molecular
mass of about 165 kDa (D-Ron) (Fig. 1). This abnormal mol-
ecule was expressed in the gastric cancer KATO-III cell line
and coexisted with the regular 150-kDa Ron b chain, albeit
expressed in low quantities.
After specific immunoprecipitation, Western blot experi-
ments with phosphotyrosine antibodies showed that the D-Ron
protein was phosphorylated on tyrosine either in the absence
or in the presence of the ligand (Fig. 2). As described before
(13), tyrosine phosphorylation of the Ron b chain is observed
only upon MSP stimulation. The Ron b chain was found phos-
phorylated in KATO-III cells also in the absence of ligand,
probably through D-Ron transphosphorylation.
The D-Ron protein originates from an alternatively spliced
mRNA. Rearrangements causing aberrant migration and de-
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regulated activity have been reported for the MET gene (30),
a RON homolog. To investigate if the D-Ron protein results
from a possible genetic damage, the full-length cDNA was
cloned from KATO-III cells. RT-PCR was performed to am-
plify partially overlapping sequences, spanning the entire RON
cDNA from position 2183 in the 59 untranslated region to
position 4242 in the 39 untranslated region, using four oligo-
nucleotide primer pairs designed on the basis of the previously
reported RON sequence (36). Several cDNA clones obtained
by amplification were sequenced on both strands (Fig. 3A).
The only mutation detected was a single G-A transversion,
resulting in a Gln-Arg substitution in the extracellular domain
at amino acid position 322. (To exclude the possibility that this
point mutation was responsible for the changes in properties of
the p165 isoform [see below], the Gln3Arg substitution at
position 322 was corrected in the D-RON cDNA by site-di-
rected mutagenesis. No changes in biochemical or biological
properties were observed [data not shown].) However, when
the region between nucleotides 2165 and 3525 was amplified,
two distinct fragments were obtained. The specificity of the
fragments was ensured by hybridization analysis with a specific
RON probe. The difference in size between the two bands
corresponded to a sequence of 147 bp, i.e., 49 amino acids,
matching the size reduction measured in D-Ron. The presence
FIG. 1. Ron receptor expression. Detergent-solubilized proteins from tumor
cell lines were immunoprecipitated with antibodies directed against the C ter-
minus of the Ron b chain, separated by SDS-PAGE under reducing conditions,
transferred to nitrocellulose paper, and probed with the same antibodies. The
specific antibodies identified one single band, with an apparent molecular mass
of 150 kDa, corresponding to the Ron b chain. When expressed at detectable
levels, the pr170RON precursor was also evident as a tightly compressed double
band. In the gastric cancer KATO-III cell line, the Ron antibodies identified a
protein with an apparent molecular mass of about 165 kDa (D-Ron) which
coexists with the 150-kDa Ron b chain, albeit expressed in low amount. Arrows
indicate the uncleaved precursor (pr170RON), the mature b chain (p150RON), and
the 165-kDa protein (p165D-RON).
FIG. 2. D-Ron is constitutively tyrosine phosphorylated in vivo. Detergent-
solubilized proteins from cells treated with conditioned medium from U293 cells,
either control (2) or MSP transfected (1), were immunoprecipitated with Ron
antibodies and Western blotted with phosphotyrosine antibodies. MSP-induced
phosphorylation of the 150-kDa Ron b chain was detectable both in KATO-III
and T47D cells, whereas the 165-kDa protein was tyrosine phosphorylated either
in the presence (1) or in the absence (2) of the ligand. In KATO-III cells, the
Ron b chain was tyrosine phosphorylated also in the absence of ligand, likely as
consequence of transphosphorylation via the constitutively tyrosine phosphory-
lated D-Ron.
FIG. 3. The D-Ron protein originates from an alternatively spliced mRNA.
(A) Schematic representation of the full-length D-RON cDNA cloned from
KATO-III cells. RT-PCR was performed to amplify partially overlapping se-
quences, spanning the entire RON cDNA from position 2183 in the 59 untrans-
lated region to position 4389 in the 39 untranslated region. Two distinct cDNA
clones were obtained during the amplification between nucleotides 2165 and
3525. All cDNA clones were sequenced on both strands. The consensus sequence
for the precursor cleavage (KRRRR), the transmembrane and kinase domains,
and the 147-bp (D) region deleted in D-RON are indicated. The three critical
cysteine residues missing in D-RON cDNA are also shown. (B) The PCR am-
plification fragments were resolved by electrophoresis in 1% agarose gel, trans-
ferred to a nylon filter, and analyzed by hybridization with the entire RON cDNA
as a probe. The difference in size of the cDNA clones between nucleotides 2165
and 3525 corresponded precisely to the length of the deletion (147 bp). One PCR
product was obtained from the corresponding region on genomic DNA extracted
from KATO-III cells. (C) The genomic PCR amplification product was se-
quenced, and exon-intron junctions were identified. The drawing represents the
partial exon-intron structure surrounding the region of divergence between the
RON and D-RON cDNAs. The alternative splicing event that generates the
D-RON transcript is indicated by the dashed line. Uppercase letters designate
coding sequences; nucleotides in the introns are in lowercase letters. The alter-
native acceptor sites are underlined. The alternative splicing of the 147-bp region
occurs through the use of an acceptor site for the 86-bp 59 intron. Its donor site,
located at the 39 end of the preceding exon, can be spliced at bp 2678, generating
the RON mRNA, or at bp 2825, generating the D-RON transcript.
5520 COLLESI ET AL. MOL. CELL. BIOL.
of two alleles (encoding a long and a short form of the protein)
was ruled out since a single PCR product, corresponding to a
size of 442 bp, was obtained from the genomic DNA (Fig. 3B).
No mutations altering the normal splicing pattern were found
in this DNA region; the genomic nucleotide sequence was
identical to that of cell lines expressing the wild-type Ron
receptor protein (T47D and GTL-16 [data not shown]).
These results can be explained only in terms of alternative
splicing of a single RON primary transcript. Indeed, a minor
cDNA variant lacking 49 amino acids has been described (13).
Two other occurrences of alternative splicing in KATO-III
cells have been reported (K-sam and E-cadherin transcripts
[19, 29]).
The relative amounts of D-RON and RON transcripts were
then quantitated in Northern analysis by differential hybridiza-
tion with a full-size RON probe or with a probe corresponding
to the 147-bp deleted fragment. The D-RON mRNA was by far
the most abundant transcript in KATO-III cells, while the
full-size RON transcript was predominant in control cell lines
(Fig. 4). These data show that the gastric cancer cell line
studied accumulates the D-RON mRNA that in other cells is a
minor component.
The D-RON transcript is missing a 147-bp cassette exon.
These data suggest that the two RON transcripts differ in the
short 147-bp sequence as a result of a differential maturation of
the primary transcript. To verify whether an alternative splic-
ing can occur, the KATO-III genomic PCR amplification prod-
uct was subcloned in the pUC18 vector and sequenced. Exon-
intron junctions were identified by comparing genomic and
cDNA sequences. This analysis showed that the 147-bp coding
sequence is flanked at both 59 and 39 ends by two short introns
of 86 and 80 bp, respectively.
The alternative splicing of the 147-bp sequence occurs
through the use of an alternative acceptor site for the 59 intron.
Its donor site, located at 39 end of the preceding exon, can be
spliced to two acceptor sites, (i) at bp 2678 and (ii) at bp 2825,
located at the origin of the 147-bp sequence and at the origin
of the following exon, respectively. In the first case, the spliced
intron is of 86 bp and the mature RNA retains the 147-bp
miniexon. A donor site at its 39 end can be spliced to the
acceptor site at position 2825, generating the second 80-bp
intron. In the second case, the first donor site is spliced to the
alternative acceptor site at bp 2825, consequently generating a
long intron that contains the 147-bp cassette exon together
with its flanking noncoding sequences (Fig. 3C). The predicted
proteins encoded by the two mRNAs differ by 49 amino acids.
Interestingly, among them are three cysteine residues. Thus,
the short protein will have an uneven number of free thiol
groups, a condition favoring interchain disulfide bond forma-
tion and stable oligomerization.
The D-Ron kinase forms oligomers in the intracellular com-
partment. To characterize the biochemical properties of the
protein encoded by D-RON, the corresponding cDNA was
expressed in COS-1 cells. As control, cells were also trans-
fected with the RON cDNA. After lysis, proteins were analyzed
by specific immunoprecipitation and Western blotting with
Ron antibodies. The pattern of migration in reducing condi-
tions of the recombinant D-Ron was found identical to that of
the native form identified in the KATO-III cell line (Fig. 5).
The heterodimeric structure of the wild-type Ron protein
was previously deduced from the different migration patterns
in reducing and nonreducing conditions (13). As expected, in
an in vitro kinase assay experiment, the shift was observed in
the immunoprecipitates obtained from cells expressing the
wild-type RON receptor. On the other hand, the p165D-RON
protein migrated to the same extent in reducing and nonre-
ducing conditions. This finding showed that p165D-RON is a
single-chain molecule, with the properties of the pr170RON
precursor, prior to its cleavage (Fig. 6A). Notably, p165D-RON,
immunoprecipitated either from KATO-III cells or from trans-
fected cells (not shown), was found in oligomers migrating as
discrete bands of high molecular weight in nonreducing con-
ditions. The oligomers, excised, reduced, and run again in the
presence of 2-mercaptoethanol, were resolved in specific 165-
kDa monomers (Fig. 6B), as confirmed by Western blotting
with Ron antibodies (not shown), showing that the complexes
FIG. 4. D-RON is the most abundant mRNA in KATO-III cells. Ten micro-
grams of total RNA extracted from KATO-III and GTL-16 cells was subjected
to differential hybridization with the full-size RON probe and with a probe
containing only the 147-bp deletion fragment. The full-size probe hybridized with
RON mRNA extracted from both cell lines. Conversely, the 147-bp deletion
probe barely detected the KATO-III mRNA, indicating that the D-RON tran-
script was by far the most abundant. A probe for the housekeeping gene glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) was used to evaluate the
amount of mRNA transferred to filters. The Northern blot was exposed for 96 h.
FIG. 5. D-RON cDNA encodes a 165-kDa protein. COS-1 cells were trans-
fected with RON or D-RON cDNA, and proteins were analyzed as described for
Fig. 1. The migration patterns of recombinant proteins immunoprecipitated from
RON- and D-RON-transfected COS-1 cells (A) corresponded to those of native
proteins extracted from T47D and KATO-III cells (B), respectively. Arrows
indicate the uncleaved precursor (pr170RON), the mature b chain (p150RON), and
the 165-kDa protein (p165D-RON). The pr170RON expressed by T47D cells mi-
grates as a doublet as consequence of differential glycosylation.
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are formed by D-Ron proteins stabilized by intermolecular
disulfide bonds. In principle, it is not possible to exclude that
heterodimerization with other proteins could also occur. How-
ever, this possibility is reduced to a minimum by the fact that
the high-molecular-weight complexes are roughly multiples (in
weight) of D-Ron monomer (330 and 660 kDa).
The possibility that intermolecular disulfide bonds, hamper-
ing D-Ron gel mobility under nonreducing conditions, were
postlysis artifacts was ruled out by adding an alkylating agent
(iodoacetamide, 50 mM) to the extraction buffer.
The mature, cleaved Ron protein is exposed at the cell
surface, as demonstrated by domain-specific surface biotinyla-
tion of T47D cells or of cells transfected with the wild-type
RON cDNA. In contrast, no biotin-labeled p165D-RON proteins
were immunoprecipitated from KATO-III cells or from COS-1
cells transiently transfected with D-RON cDNA (Fig. 7). These
data show that the deleted D-Ron is retained in the intracel-
lular compartment, possibly in the pre-Golgi vesicular system,
as indicated by endoglycosidase-H digestion susceptibility
(data not shown).
D-Ron oligomers originate by intermolecular disulfide bond-
ing. To confirm that intracellular oligomerization of D-Ron is
due to the uneven number of cysteine residues, we generated
the mutant C914A-Ron. One of the highly conserved cysteine
residues (position 914, included in the 49-amino-acid deletion
fragment) was converted to alanine by site-directed mutagen-
esis. Expression in COS-1 cells of the mutated cDNA was
followed by accumulation of the Ron single-chain precursor
(pr170RON) and retention in the intracellular compartment.
The mutant with uneven cysteine residues was constitutively
phosphorylated on tyrosine (Fig. 8A), mimicking that occur-
ring in the D-Ron isoform.
Covalent disulfide bonding is known to be reversible in the
presence of reducing agents. Therefore, we added exogenous
2-mercaptoethanol to cells naturally expressing D-Ron (KATO-
III) at concentrations not affecting cell viability, terminal gly-
cosylation, or membrane exposure of proteins (1). Mercap-
toethanol allowed maturation of D-Ron, and the correctly
processed ab heterodimer was exposed to the cell surface
(Fig. 8B). The effect of 2-mercaptoethanol was dose depen-
dent, ranging from 2 to 32 mM (maximal activity). Under these
conditions, the high-molecular-weight D-Ron aggregates dis-
appeared (data not shown), confirming the central role played
by free thiol groups.
D-Ron induces cell motility and invasiveness. Under physi-
ological conditions, the Ron receptor transduces mitogenic,
motogenic, and invasive signals when stimulated by the growth
factor MSP (25). The ligand-independent tyrosine phosphory-
lation of D-Ron prompted us to verify if constitutive activation
of Ron could be associated with transformation and/or acqui-
sition of an invasive phenotype.
Surprisingly, NIH 3T3 cells transfected by D-RON and ex-
pressing the constitutively activated kinase did not form foci of
transformation, nor did they grow in soft agar.
A motility assay was then performed to measure the chemo-
tactic and chemokinetic properties of a panel of cells express-
ing the wild-type Ron or D-Ron. As a control, cells not ex-
pressing Ron were studied. Figure 9 shows that the latter were
inactive, either in the absence or in the presence of MSP; as
expected, the cells expressing wild-type Ron migrated only in
the presence of MSP. Interestingly, the cells expressing D-Ron
displayed a constitutive motile phenotype. This phenotype was
driven either by the endogenous D-Ron, the recombinant
D-Ron (cloned from KATO-III cells), or the mutant C914A-
Ron, bearing an uneven number of cysteine residues. Notably,
the motile-invasive phenotype was expressed constitutively also
by NIH 3T3 cells stably transfected with D-Ron and expressing
a normal level of protein.
An invasion assay was also performed to assess the ability of
D-Ron to drive migration through an artificial basement mem-
brane, made of collagen IV, laminin, and glycosaminoglycans.
FIG. 6. The D-Ron protein is an oligomerized, single-chain, active tyrosine
kinase. (A) Proteins solubilized from control (T47D) cells and from KATO-III
cells were immunoprecipitated with Ron antibodies. A kinase assay was per-
formed on immunocomplexes as described in Materials and Methods. Radiola-
beled proteins were separated by SDS-PAGE (5 to 10% gradient gel) under
reducing (b1) or nonreducing (b2) conditions. Gels were alkali treated, dried,
and exposed for autoradiography with intensifying screens. A major tyrosine-
phosphorylated band of 150 kDa, corresponding to the Ron b chain, was evident.
As expected, under nonreducing conditions, the 150-kDa protein, immunopre-
cipitated from T47D and KATO-III cells, shifted from 150 to 185 kDa because
of its association with the a chain. In contrast, the p165D-RON protein migrated
at the same extent both in reducing and nonreducing conditions. The immuno-
complexes from KATO-III cells, analyzed by SDS-PAGE in the absence of
2-mercaptoethanol, contained high-molecular-weight oligomers, indicated by the
asterisks. The high-molecular-weight bands, excised from the dried gel and
reanalyzed under reducing conditions, were resolved in 165-kDa D-Ron mono-
mers (B). Arrows indicate the mature ab heterodimer (p185RON), the 150-kDa
b chain, and the uncleaved p165D-RON protein. Molecular weights are indicated
in thousands.
FIG. 7. D-Ron is not exposed at the cell surface. COS-1 cells transfected with
both RON and D-RON cDNAs, T47D cells expressing endogenous Ron, and
KATO-III cells expressing endogenous D-Ron were subjected to domain-selec-
tive cell surface biotinylation. Proteins from cell lysates were immunoprecipi-
tated with Ron antibodies, separated by SDS-PAGE under reducing conditions,
and transferred to nitrocellulose. Biotinylated proteins were visualized by using
streptavidin-horseradish peroxidase and ECL. The mature 150-kDa Ron protein
from T47D cells and KATO-III cells was exposed at the cell surface (A) as well
as the recombinant Ron (B). D-Ron, both endogenous and recombinant, was
retained in the intracellular compartment.
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Again, the cells expressing the full-size Ron, either endoge-
nous or transfected, were found to cross the basement mem-
brane only after stimulation with MSP. On the other hand, the
cells expressing D-Ron or the C914A-Ron mutant constitu-
tively displayed invasive properties (Fig. 10).
DISCUSSION
Structural alterations of oncogene-coded proteins can de-
regulate critical cellular functions. Several examples have been
reported for tyrosine kinase receptors, such as the activating
rearrangements of TRK, RET, and MET (9, 24, 41). Moreover
59 or 39 deletions activate v-erbB (12), v-kit (33), v-fms (47), and
HER2 (5). The data presented here demonstrate the existence
of a structurally altered form of the tyrosine kinase receptor
encoded by the RON gene. This isoform (D-Ron) is generated
by alternative splicing, segregates in the intracellular compart-
ment, oligomerizes by stable intermolecular disulfide bonds,
and displays constitutive tyrosine phosphorylation. The cells
expressing D-Ron acquire a migratory and invasive phenotype.
D-Ron differs from the full-length sequence by lacking 49
amino acids in the extracellular domain. The two transcripts,
encoding full-size Ron and the D-Ron isoform, are generated
by alternative splicing of a true cassette exon of 147 bp encod-
ing a short segment of the extracellular domain. Cassette exons
are nucleotide sequences that may or may not be incorporated
into mRNA, but their immediate flanking introns are invari-
ably removed during the splicing process (6). In the case of the
RON mRNA, when the introns flanking the cassette exon are
individually removed, the 147 bp are included in the mature
transcript; when the flanking introns are removed together, the
embodied cassette exon is spliced out and the D-RON mRNA
is generated. The second event is due to the existence, at the
boundary between the 59 intron and the 147-bp cassette exon,
of a noncanonical 39 splice site consensus sequence (-TA in-
stead of -GT) which can be randomly ignored by the splicing
machinery. In general, it has been shown that the selection of
a splice site depends not only on its own sequence but also on
the context around that sequence (28). Regarding this point,
exons that are intrinsically poor splicing substrates, because of
small size or weak flanking splice sites, have been proposed to
FIG. 8. D-Ron oligomers formation is thiol mediated. (A) Expression in
COS-1 cells of the C914A-Ron mutant (bearing an uneven number of cysteines)
is followed by accumulation in the intracellular compartment of the single-chain
precursor (pr170RON) and by constitutive tyrosine phosphorylation, mimicking
what occurs for the D-Ron isoform. Detergent-solubilized proteins from surface-
biotinylated (SURF. BIOT.) cells were immunoprecipitated with Ron antibodies
(a-Ron), separated by SDS-PAGE under reducing conditions, and Western
blotted (W.B.) with the indicated antibodies. Biotinylated proteins were visual-
ized by using streptavidin-horseradish peroxidase and ECL. Arrows indicate the
uncleaved precursor (pr170RON), the D-Ron protein (p165D-RON), and the ma-
ture Ron b chain (p150RON). a-PTyr, antiphosphotyrosine. (B) Covalent disul-
fide bonds are reversible in the presence of reducing agents. KATO-III cells,
treated with millimolar concentrations of 2-mercaptoethanol, were subjected to
domain-selective cell surface biotinylation. Detergent-solubilized proteins were
immunoprecipitated and blotted with Ron antibodies. Biotinylated proteins were
visualized as described above. Arrows indicate the D-Ron protein (p165D-RON),
the 150-kDa Ron protein (p150RON), and the mature 140-kDa D-Ron b chain
(p140D-RON). The lane labeled with an asterisk contains D-Ron immunoprecipi-
tates obtained from cells permeabilized to allow biotin labeling of intracellular
proteins.
FIG. 9. D-Ron induces a motile phenotype in vitro. A motility assay was
performed to measure chemotactic and chemokinetic properties of a panel of
cells expressing Ron and D-Ron, either endogenous or transfected. As control,
cells not expressing Ron (MKN-1 cells) were studied. Cells were plated on the
upper side of an 8-mm-pore-size Millipore filter in a Transwell chamber and
incubated for 24 h in serum-free medium, either in the absence or in the
presence of 20 ng of MSP per ml in the lower compartment. The reported values
(averages of triplicate determinations) represent the A595 of cells that migrated
to the lower side of the Transwell and were fixed and stained with crystal violet.
The cells expressing endogenous or recombinant Ron (T47D, COS-1, and NIH
3T3 cells transfected with RON cDNA) migrated into the lower compartment of
the chamber only in the presence of MSP. Cells expressing endogenous or
recombinant D-Ron (KATO-III, COS-1, and NIH 3T3 cells transfected with
D-RON) displayed a motile phenotype also in the absence of MSP. Constitutive
migration was observed also in cells expressing the C914A-Ron mutant.
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contain positive-acting splicing elements, referred to as exon-
splicing enhancers (17, 42, 48). Canonical exon-splicing en-
hancer sequences were, however, not easily identifiable in the
147-bp cassette-exon region.
As noted above, most of the known structural defects lead-
ing to oncogene activation are due to genetic alterations such
as mutations, deletions, or rearrangements. The mechanism
leading to the generation of the constitutively tyrosine phos-
phorylated D-Ron in the cell line studied is posttranscriptional.
Posttranscriptional activation has also been observed in the
case of the homologous Met/HGF receptor. In a colon carci-
noma, accumulation of the uncleaved precursor was responsi-
ble for constitutive activation of the intrinsic tyrosine kinase. In
this case, however, the precursor accumulation was due to lack
of a specific proteolytic enzyme of the trans-Golgi network
rather than to an intrinsic structural defect of the protein (26).
The in-frame deletion induces a critical change in the D-Ron
structure. Among the missing 49 amino acids are three cysteine
residues normally involved in intramolecular disulfide bonds.
Therefore, the unbalance of the cysteine pairs renders the
uneven cysteines available for intermolecular disulfide bonding
with other D-Ron partners, creating oligomers. The existence
of high-molecular-weight D-Ron complexes sensitive to reduc-
ing agents strongly supports this hypothesis. This situation has
already been shown to occur in the case of epidermal growth
factor and erythropoietin receptor mutants (40, 46), and a
similar mechanism has been proposed for constitutive activa-
tion of the epidermal growth factor, Neu, and fibroblast growth
factor receptors (27, 39). Another example is the germ line
mutation, occurring in the multiple endocrine neoplasia 2A
(MEN2A) syndrome, that activates RET by replacement of
Cys-634; the receptor, containing an uneven number of thiol
groups, undergoes steady-state dimerization and constitutive
tyrosine kinase activation (38). Moreover, in the case of the
TRK oncogene, a 51-amino-acid deletion in the extracellular
domain, removing one cysteine residue, generates a conforma-
tion usually achieved by ligand binding (10). We reproduced
biochemical and biological properties of D-Ron by substitution
of a single cysteine residue in the extracellular domain. COS-1
cells expressing the C914A-Ron mutant, bearing an uneven
number of cysteines, were endowed with deregulated motile-
invasive properties, mimicking the phenotype elicited by
D-Ron.
The D-Ron molecules oligomerized by interchain cysteine
oxidation never reach the cell surface, nor are they correctly
processed by proteolytic cleavage. In the Met/HGF receptor, a
molecule highly homologous to Ron, a 51-amino-acid deletion
variant (with an uneven number of cysteine residues) is not
correctly processed and is retained intracellularly (35). This is
somewhat expected, since as a rule, only proteins that have
attained the proper three-dimensional structure are secreted
or expressed at the cell surface. Folding and assembly inter-
mediates are retained intracellularly. This quality control of
newly synthesized molecules takes place notably in the endo-
plasmic reticulum (18, 20, 31). For example, it has been shown
that the transport of immunoglobulin l light chains with ex-
posed thiols is hindered by the formation of reversible disulfide
bonds with the protein matrix of the endoplasmic reticulum
(34). Such interactions may be prevented by altering the intra-
cellular redox potential or by site-directed mutagenesis of one
relevant cysteine residue, as demonstrated in the case of se-
cretion of immunoglobulin M assembly intermediates (1). Sim-
ilarly, we show here that maturation and cell surface exposure
of D-Ron can be restored by addition of 2-mercaptoethanol.
This observation indicates that disulfide-interchange reactions
are responsible for the intracellular retention of D-Ron in the
form of partially assembled intermediates.
Accumulation of the misfolded immature D-Ron protein in
the intracellular vesicular compartment and its oligomerization
due to aberrant intermolecular disulfide bonds have important
consequences on receptor functions. The receptor kinase is
FIG. 10. D-Ron induces an invasive phenotype in vitro. An invasion assay was
performed to monitor the ability of cells to migrate through an 8-mm-pore-size
Millipore filter coated with an artificial basement membrane made of polymer-
ized collagen IV, laminin, and glycosaminoglycans (Matrigel). The cells express-
ing recombinant full-size Ron required stimulation by exogenous MSP to cross
the Matrigel barrier. Cells expressing recombinant D-Ron or the C914A-Ron
mutant displayed the invasive phenotype constitutively.
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constitutively activated, and the downstream motile-invasive
program is induced in the absence of exogenous signaling. As
observed, the affected cells acquire a phenotype characterized
by the ability to migrate through basement membranes in vitro.
This property correlates with the metastatic phenotype dis-
played in vivo by malignant cells (2, 43, 44). Interestingly,
although cells expressing a constitutively activated Ron ty-
rosine kinase are invasive, they do not form foci of transfor-
mation in vitro, nor do they grow in soft agar. This observation
strengthens the prominent biological features of the tyrosine
kinase receptor subfamily to which Ron belongs, i.e., the con-
trol of cell dissociation, motility, and invasion, rather than
mere growth.
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